# A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

> **NCT05265286** · PHASE2 · COMPLETED · sponsor: **Jiangsu Gensciences lnc.** · enrollment: 15 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** FRSW117

## Key facts

- **NCT ID:** NCT05265286
- **Lead sponsor:** Jiangsu Gensciences lnc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-14
- **Primary completion:** 2022-08-21
- **Final completion:** 2022-08-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265286, "A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05265286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*